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2017 Hospital Profile
Overview / Size Payer Mix
Hospital System Affiliation: Public Payer Mix:
Change in Ownership (FY13-17): CY16 Commercial Statewide Relative Price:
Total Staffed Beds: Top 3 Commercial Payers:
% Occupancy:
Special Public Funding:
Change FY16-FY17:
Financial Emergency Department Visits in FY17:
Inpatient NPSR per CMAD: Change FY16-FY17:
Outpatient Visits in FY17:
For descriptions of the metrics, please see the technical appendix.
Not Applicable
Not Applicable
Trauma Center Designation: Not Applicable
Case Mix Index:
Blue Cross Blue Shield of Massachusetts
Harvard Pilgrim Health Care
Tufts Associated HMO, Inc.
Change FY16-FY17: -18.3% 286,582
Inpatient:Outpatient Revenue in FY17:
45.9% (Non-HPP* Hospital)
-17.9%
Utilization
4.04> statewide (1.12)
Inpatient Discharges in FY17:
Dana-Farber Cancer Institute and Subsid.
0
Not Applicable 1.37
30
93.2%
1,043
 
5%:95% Change FY16-FY17: 6.4%
$11,342
DANA-FARBER CANCER INSTITUTE
Boston, MA
Specialty Hospital
Metro Boston
Dana-Farber Cancer Institute is a nonprofit specialty hospital dedicated to pediatric and adult cancer treatment and research, located in the Metro Boston 
region. It is a teaching affiliate of Harvard Medical School. It is one of 49 Comprehensive Cancer Centers in the US, designated by the National Cancer 
Institute. Dana-Farber Cancer Institute provides the majority of its care in an outpatient setting and had 1,043 inpatient discharges compared to 286,582 
outpatient visits in FY17.  Dana-Farber has posted profits in each year of the five-year period.
Change FY12-FY16 (percentage points):
Outpatient Revenue in FY17: $836,977,392
Quality
Early Elective Deliveries Rate: Not Applicable
What proportion of adult patient discharges from this hospital resulted 
in a readmission at any hospital within 30 days, and how does this 
compare to the state average?
How many central line-associated blood stream infections (CLABSI), 
catheter-associated urinary tract infections (CAUTI), and surgical site 
infections (SSI) after colon surgery did patients get at this hospital 
compared to what was expected based on the hospital's characteristics 
and case mix?
Total Revenue in FY17: $1,570,742,696
Total Surplus (Loss) in FY17: $29,886,837
Change FY16-FY17: 7.0%
Readmission Rate in FY16:
What were the most common inpatient cases (DRGs) treated at the 
hospital in FY17? What proportion of the region’s cases did this 
hospital treat for each service? 
Where did most of the hospital's inpatients reside? What proportion of 
each community's total discharges was attributed to this hospital?
 - - - Hospital  (1,043) = 0%  of total regional  discharges 
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This measure is not applicable to the patient 
 population treated at this specialty hospital 
Data is not available for these measures. 
This graph has been suppressed, as the hospital 
provides the vast majority of its services on an 
outpatient basis. In FY17, this hospital reported 
148,671 infusion treatments and over 286,000 
outpatient visits. 
This graph has been suppressed, as no 
community accounted for more than 2% of 
the hospital's total discharges. 
A58
Key:
Hospital
Cohort: Specialty Hospital Peer Cohort
For descriptions of the metrics, please see the technical appendix.
* High Public Payer Hospitals (HPP) receive a minimum of 63% of gross patient service revenue from public payers.
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How has the volume of the hospital's inpatient discharges changed 
compared to FY13, and how does this compare to the hospital's peer 
cohort median? (FY13=100)
How has the volume of the hospital's outpatient visits changed 
compared to FY13, and how does this compare to the hospital's peer 
cohort median? (FY13=100)
What was the hospital's net inpatient service revenue per case mix 
adjusted discharge between FY13 and FY17, and how does this 
compare to the hospital's peer cohort median?
How has the hospital's total outpatient revenue changed compared to 
FY13, and how does this compare to the hospital's peer cohort 
median? (FY13=100)
How have the hospital's total revenue and costs changed between 
FY13 and FY17?
What were the hospital's total margin and operating margins between 
FY13 and FY17, and how do these compare to the hospital's peer 
cohort medians?
Revenue, Cost, & Profit/Loss (in millions)
FY 2013 2014 2015 2016
141.4$   
 Operating Revenue 974.6$   1,019$   1,117$   1,293$   1,429$   
Non-Operating 
Revenue
103.6$   78.7$     53.2$     88.1$     
1,541$   
Total Revenue 1,078$   1,098$   1,171$   1,382$   1,571$   
Total Costs 1,022$   1,064$   1,166$   1,338$   
Total Profit (Loss) 56.2$     34.6$     4.7$       43.3$     29.9$     
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